Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas
NCT06747728Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab in glioma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate at 2 years. Started Mar 2024; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06747728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747728.